Hope for 14 Million+ Rosacea Sufferers

48-Week Clinical Study of Pyratine XRTM Shows Significant Reductions of All Three Major Symptoms of Rosacea

April is Rosacea Awareness Month

According to the National Rosacea Society, there are more than 14 million people in the United States with rosacea, yet only a small number are being treated. Rosacea is a chronic condition that often requires extended treatment periods which often cause side effects, and treatments that provide sustained relief of the signs and symptoms of rosacea are needed. Current topical agents can cause high skin sensitivity and oral antibiotics are not suitable for continuous long-term use due to concerns about thier affect on healthy intestinal bacteria.

A new cosmesecutical, Pyratine XR, may offer them hope. A recent study conducted at the University of California, Irvine, of mild to moderate rosacea patients found that Pyratine XR – a non-prescription, physician-dispensed product – showed improvement for all of the major signs and symptoms of rosacea. The study findings were just presented at both the American Academy of Dermatology’s annual meeting and the South Beach Clinical Dermatology Symposium.

After the 48-week clinical trial, there was an overall clinical improvement in 80% of subjects. The investigators saw continual, statistically significant mean improvement, including a 90% improvement in lesions, 45% improvement in erythema (redness) and a 28% improvement in telangiectasia (spider veins). As early as week 4, there was significant improvement in skin barrier function, decrease of water loss, and a 41% mean improvement in skin dryness. The product was well tolerated by all subjects.

Video from: Senetek